Non-Cystic Fibrosis Bronchiectasis (NCFB) Epidemiology

DelveInsight’s ‘Non-cystic Fibrosis Bronchiectasis (NCFB) – Epidemiology Forecast – 2034’ report delivers an in-depth understanding of the Non-cystic Fibrosis Bronchiectasis, historical and forecasted epidemiology as well as the Non-cystic Fibrosis Bronchiectasis trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, Japan, and China.

Geographies Covered

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan
• China

Study Period: 2021-2034

Non-cystic Fibrosis Bronchiectasis Disease Understanding

Non-cystic Fibrosis Bronchiectasis is a chronic inflammatory lung disease. It is characterized by permanent dilatation of the bronchial tree, leading to chronic sputum production and impaired bacterial clearance. The affected parts of the lungs develop a vicious cycle of failed pathogen clearance leading to frequent infections, chronic inflammation, and ongoing structural damage. The main symptoms are cough, sputum production, and frequent respiratory infections.

It is associated with comorbidities, such as anxiety, depression, and fatigue, significantly impacting the quality of life. Patients with NCFB require longer hospital stays and more outpatient visits. The etiology of NCFB is multifactorial, but most cases are idiopathic or post-infective. NCFB patients are considered at risk of Pseudomonas aeruginosa.

Symptoms include shortness of breath, wheezing, coughing blood, and chest pain. Patients often have recurrent chest infections. The severity of symptoms can vary widely. Some people have a few symptoms that do not often appear, while others have wide-ranging daily symptoms. The symptoms worsen if the patient develops an exacerbation (usually caused by a chest infection).

Bronchiectasis is generally progressive, but it can be difficult to predict long-term outcomes. There are currently two scoring systems for predicting mortality in bronchiectasis; the Bronchiectasis Severity Index (BSI) and the FACED (F: forced expiratory volume in 1 s [FEV1]; A: age; C: chronic colonization by Pseudomonas aeruginosa [PA], E: radiological extension [number of pulmonary lobes affected], and D: dyspnea score). Both systems are validated to predict future mortality rates, and the BSI also predicts the future risk of hospitalization for 1 and 4 years.

Non-cystic Fibrosis Bronchiectasis Diagnosis

Bronchiectasis is diagnosed via a chest computed tomography (CT) scan. A chest X-ray, bronchoscopy, lung function, blood tests, sputum culture, and other tests (e.g., immune function, sweat test, and genetics) for associated diseases may also be performed. Before a diagnosis of bronchiectasis is made, symptoms are often attributed to asthma or a viral infection. If a chronic wet cough fails to respond to 4 weeks of appropriate antibiotics, it increases the probability of underlying bronchiectasis and is an indication for referral to a specialty respiratory service.

Continued in the report…..         

Non-cystic Fibrosis Bronchiectasis Epidemiology Perspective by DelveInsight

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Diagnosed prevalent cases of Non-cystic Fibrosis Bronchiectasis, Gender-specific cases of Non-cystic Fibrosis Bronchiectasis, Severity-specific cases of Non-cystic Fibrosis Bronchiectasis, Etiology-associated cases of Non-cystic Fibrosis Bronchiectasis, and Microbiology of Non-cystic Fibrosis Bronchiectasis patients scenario of Non-cystic Fibrosis Bronchiectasis in the 7MM + China covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, Japan, and China from 2021 to 2034.

Non-cystic Fibrosis Bronchiectasis Detailed Epidemiology Segmentation

• In 2022, the diagnosed prevalent cases of Non-cystic Fibrosis Bronchiectasis were estimated to be approximately 9,397,292 cases in the 7MM + China. These cases are expected to increase by 2034 at a CAGR of 1.4% during the study period (2021-2034).
• Among the 7MM, the United States accounted for approximately 3.9% of the total diagnosed cases of Non-cystic Fibrosis Bronchiectasis in the 7MM + China in 2022, which is expected to increase further during the study period (2021-2034).
• In EU4 and the UK, females diagnosed with Non-cystic Fibrosis Bronchiectasis are higher in number than males. In 2022, the cases of Non-cystic Fibrosis Bronchiectasis among females in EU4 and the UK were reported to be approximately 260,860, while among the male population, there were around 231,259 cases of Non-cystic Fibrosis Bronchiectasis. These numbers are expected to rise during the study period (2021-2034).
• In Japan, severe cases of Non-cystic Fibrosis Bronchiectasis are the highest, followed by moderate cases of Non-cystic Fibrosis Bronchiectasis and mild cases of Non-cystic Fibrosis Bronchiectasis. In 2022, there were approximately 284,873 severe cases of Non-cystic Fibrosis Bronchiectasis, around 125,833 moderate cases of Non-cystic Fibrosis Bronchiectasis, and approximately 78,346 mild cases of Non-cystic Fibrosis Bronchiectasis, which are expected to decrease during the study period (2021-2034).
• Unknown/idiopathic are the most prevalent Non-cystic Fibrosis Bronchiectasis etiology cases in China, followed by other etiologies and asthma associated with Non-cystic Fibrosis Bronchiectasis. In 2022, around 3,058,177 unknown/idiopathic cases of Non-cystic Fibrosis Bronchiectasis were reported in China, which is expected to increase during the study period (2021-2034).
• In 2022, there were approximately 132,872 P. aeruginosa cases of Non-cystic Fibrosis Bronchiectasis in EU4 and the UK, followed by approximately 113,187 H. influenza cases of Non-cystic Fibrosis Bronchiectasis, and approximately 108,266 no pathogen growth Non-cystic Fibrosis Bronchiectasis cases. These numbers are expected to rise during the study period (2021-2034).

Scope of the Report

• The report covers a descriptive overview of Non-cystic Fibrosis Bronchiectasis, explaining its symptoms, grading, pathophysiology, and various diagnostic approaches.
• The report provides insight into the 7MM + China historical and forecasted patient pool covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, Japan, and China.
• The report assesses the disease risk and burden of Non-cystic Fibrosis Bronchiectasis.
• The report helps to recognize the growth opportunities in the 7MM + China concerning the patient population.
• The report provides the segmentation of the disease epidemiology for the 7MM + China, Diagnosed prevalent cases of Non-cystic Fibrosis Bronchiectasis, Gender-specific cases of Non-cystic Fibrosis Bronchiectasis, Severity-specific cases of Non-cystic Fibrosis Bronchiectasis, Etiology-associated cases of Non-cystic Fibrosis Bronchiectasis, and Microbiology of Non-cystic Fibrosis Bronchiectasis patients.

Unlock comprehensive insights into the Non-Cystic Fibrosis Bronchiectasis (NCFB) market. Explore our detailed epidemiology and market forecast for 2034.

Report Highlights

• 10-year Forecast of Non-cystic Fibrosis Bronchiectasis
• The 7MM + China Coverage
• Diagnosed prevalent cases of Non-cystic Fibrosis Bronchiectasis
• Gender-specific cases of Non-cystic Fibrosis Bronchiectasis
• Severity-specific cases of Non-cystic Fibrosis Bronchiectasis
• Etiology-associated cases of Non-cystic Fibrosis Bronchiectasis
• Microbiology of Non-cystic Fibrosis Bronchiectasis patients

Key Questions Answered

• What are the disease risk and burdens of Non-cystic Fibrosis Bronchiectasis?
• What is the historical Non-cystic Fibrosis Bronchiectasis patient pool in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, Japan, and China?
• What would be the forecasted patient pool of Non-cystic Fibrosis Bronchiectasis at the 7MM + China level?
• What will be the growth opportunities across the 7MM + China concerning the patient population with Non-cystic Fibrosis Bronchiectasis?
• Out of the countries mentioned above, which country would have the highest prevalent population of Non-cystic Fibrosis Bronchiectasis during the forecast period (2025-2034)?
• At what CAGR is the population expected to grow across the 7MM + China during the forecast period (2025-2034)?

Reasons to Buy

The Non-cystic Fibrosis Bronchiectasis report will allow the user to -

• Develop business strategies by understanding the trends shaping and driving the 7MM + China Non-cystic Fibrosis Bronchiectasis epidemiology forecast.
• The Non-cystic Fibrosis Bronchiectasis epidemiology report and model were written and developed by Master’s and Ph.D. level epidemiologists.
• The Non-cystic Fibrosis Bronchiectasis epidemiology model developed by DelveInsight is easy to navigate, interactive with a dashboard, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports the data presented in the report and showcases disease trends over the 10-year forecast period using reputable sources.

Key Assessments

• Patient segmentation
• Disease risk and burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population